Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder characterized by cognitive deficit and pathological accumulation of amyloid-β (Aβ) and tau proteins. The rodent models have contributed greatly to unravel AD pathogenesis, but these AD models have been shown a modest clinical translational effectiveness.
Objective
Therefore, developing mass-producible primate AD models is promising for more effective drug development.
Methods
Here, we constructed the AD monkey models by simultaneously infusing AAV-Tau and Aβ into different brain regions.
Results
The induced monkeys showed a durable cognitive impairment lasting for at least 10 months after the modeling. Simultaneously, the increased levels of total tau and hyperphosphorylated tau (pTau) at several AD-associated sites, and neurofilament light chains (NfL) with altered Aβ level were detected at different time points in cerebrospinal fluid and/or plasma by using MSD kits. The increased brain accumulation of Aβ and tau proteins was also detected by positron emission tomography/magnetic resonance imaging and immunohistochemical staining. The model monkeys also had significant glial activation; an indicator of inflammation commonly seen in the brains of AD patients.
Conclusions
Together, this study provides mass-producible monkey models showing durable AD-like hallmark pathologies (Aβ, tau, NfL, i.e., ATN) and cognitive deficits. As monkeys are genetically and metabolically the closest to humans, these models will offer more effective drug discovery and development for AD.
KnopmanDSAmievaHPetersenRC, et al.Alzheimer disease. Nat Rev Dis Primers2021; 7: 33.
2.
HampelHHardyJBlennowK, et al.The amyloid-beta pathway in Alzheimer's disease. Mol Psychiatry2021; 26: 5481–5503.
3.
JagustWJTeunissenCEDeCarliC. The complex pathway between amyloid beta and cognition: implications for therapy. Lancet Neurol2023; 22: 847–857.
4.
SimonsMLevinJDichgansM. Tipping points in neurodegeneration. Neuron2023; 111: 2954–2968.
5.
NiJXieZQuanZ, et al.How brain ‘cleaners’ fail: mechanisms and therapeutic value of microglial phagocytosis in Alzheimer's disease. Glia2024; 72: 227–244.
6.
van DyckCHSwansonCJAisenP, et al.Lecanemab in early Alzheimer's disease. N Engl J Med2023; 388: 9–21.
7.
SinghPKSimoes-PiresENChenZL, et al.Lecanemab blocks the effects of the Abeta/fibrinogen complex on blood clots and synapse toxicity in organotypic culture. Proc Natl Acad Sci U S A2024; 121: e2314450121.
8.
ManlyJJDetersKD. Donanemab for Alzheimer disease-who benefits and who is harmed?JAMA2023; 330: 510–511.
9.
LiuEZhangYWangJZ. Updates in Alzheimer's disease: from basic research to diagnosis and therapies. Transl Neurodegener2024; 13: 45.
10.
LiHLWangHHLiuSJ, et al.Phosphorylation of tau antagonizes apoptosis by stabilizing beta-catenin, a mechanism involved in Alzheimer's neurodegeneration. Proc Natl Acad Sci U S A2007; 104: 3591–3596.
11.
LiuEZhouQXieAJ, et al.Tau acetylates and stabilizes beta-catenin thereby promoting cell survival. EMBO Rep2020; 21: e48328.
12.
LuoHBXiaYYShuXJ, et al.SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination. Proc Natl Acad Sci U S A2014; 111: 16586–16591.
13.
ZhengJLiHLTianN, et al.Interneuron accumulation of phosphorylated tau impairs adult hippocampal neurogenesis by suppressing GABAergic transmission. Cell Stem Cell2020; 26: 331–345 e336.
14.
WuDYuNGaoY, et al.Targeting a vulnerable septum-hippocampus cholinergic circuit in a critical time window ameliorates tau-impaired memory consolidation. Mol Neurodegener2023; 18: 23.
15.
WuDGaoDYuH, et al.Medial septum tau accumulation induces spatial memory deficit via disrupting medial septum-hippocampus cholinergic pathway. Clin Transl Med2021; 11: e428.
16.
YinYGaoDWangY, et al.Tau accumulation induces synaptic impairment and memory deficit by calcineurin-mediated inactivation of nuclear CaMKIV/CREB signaling. Proc Natl Acad Sci U S A2016; 113: E3773–E3781.
17.
FengQLuoYZhangXN, et al.MAPT/Tau accumulation represses autophagy flux by disrupting IST1-regulated ESCRT-III complex formation: a vicious cycle in Alzheimer neurodegeneration. Autophagy2020; 16: 641–658.
18.
LiMZLiuEJZhouQZ, et al.Intracellular accumulation of tau inhibits autophagosome formation by activating TIA1-amino acid-mTORC1 signaling. Mil Med Res2022; 9: 38.
19.
LiXCHuYWangZH, et al.Human wild-type full-length tau accumulation disrupts mitochondrial dynamics and the functions via increasing mitofusins. Sci Rep2016; 6: 24756.
20.
Welsh-BohmerKAKerchnerGADhaddaS, et al.Decision making in clinical trials: interim analyses, innovative design, and biomarkers. Alzheimers Dement (N Y)2023; 9: e12421.
21.
HardyJSelkoeDJ. Medicine – the amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science2002; 297: 353–356.
22.
SerenoMITootellRBH. From monkeys to humans: what do we now know about brain homologies?Curr Opin Neurobiol2005; 15: 135–144.
23.
WalshDMTsengBPRydelRE, et al.The oligomerization of amyloid β-protein begins intracellularly in cells derived from human brain. Biochemistry2000; 39: 10831–10839.
24.
SaniSTraulDKlinkA, et al.Distribution, progression and chemical composition of cortical amyloid-beta deposits in aged rhesus monkeys: similarities to the human. Acta Neuropathol2003; 105: 145–156.
25.
GiannakopoulosPSilholSJallageasV, et al.Quantitative analysis of tau protein-immunoreactive accumulations and beta amyloid protein deposits in the cerebral cortex of the mouse lemur, Microcebus murinus. Acta Neuropathol1997; 94: 131–139.
26.
GeulaCNagykeryNWuCK. Amyloid-beta deposits in the cerebral cortex of the aged common marmoset (Callithrix jacchus): incidence and chemical composition. Acta Neuropathol2002; 103: 48–58.
27.
ArnstenAFTDattaDLeslieS, et al.Alzheimer's-like pathology in aging rhesus macaques: unique opportunity to study the etiology and treatment of Alzheimer's disease. Proc Natl Acad Sci U S A2019; 116: 26230–26238.
28.
TuZYanSHanB, et al.Tauopathy promotes spinal cord-dependent production of toxic amyloid-beta in transgenic monkeys. Signal Transduct Target Ther2023; 8: 358.
29.
YueFFengSLuC, et al.Synthetic amyloid-beta oligomers drive early pathological progression of Alzheimer's disease in nonhuman primates. Iscience2021; 24: 103207.
30.
BeckmanDChakrabartyPOttS, et al.A novel tau-based rhesus monkey model of Alzheimer's pathogenesis. Alzheimers Dement2021; 17: 933–945.
31.
JiangZWangJQinY, et al.A nonhuman primate model with Alzheimer's disease-like pathology induced by hippocampal overexpression of human tau. Alzheimers Res Ther2024; 16: 22.
32.
BuscheMAHymanBT. Synergy between amyloid-beta and tau in Alzheimer's disease. Nat Neurosci2020; 23: 1183–1193.
33.
PassamontiLVazquez RodriguezPHongYT, et al.18F-AV-1451 Positron emission tomography in Alzheimer's disease and progressive supranuclear palsy. Brain2017; 140: 781–791.
34.
SchollMOssenkoppeleRStrandbergO, et al.Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease. Brain2017; 140: 2286–2294.
35.
LeuzyAMattsson-CarlgrenNPalmqvistS, et al.Blood-based biomarkers for Alzheimer's disease. EMBO Mol Med2022; 14: e14408.
36.
PoisnelGDhillyMMoustieO, et al.PET Imaging with [18F]AV-45 in an APP/PS1-21 murine model of amyloid plaque deposition. Neurobiol Aging2012; 33: 2561–2571.
37.
SchmidtMLRobinsonKALeeVM, et al.Chemical and immunological heterogeneity of fibrillar amyloid in plaques of Alzheimer's disease and down's syndrome brains revealed by confocal microscopy. Am J Pathol1995; 147: 503–515.
38.
DesaiPPIkonomovicMDAbrahamsonEE, et al.Apolipoprotein D is a component of compact but not diffuse amyloid-beta plaques in Alzheimer's disease temporal cortex. Neurobiol Dis2005; 20: 574–582.
39.
MattssonNCullenNCAndreassonU, et al.Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol2019; 76: 791–799.
40.
MoscosoAGrotheMJAshtonNJ, et al.Longitudinal associations of blood phosphorylated Tau181 and neurofilament light chain with neurodegeneration in Alzheimer disease. JAMA Neurol2021; 78: 396–406.
41.
SelfWKHoltzmanDM. Emerging diagnostics and therapeutics for Alzheimer disease. Nat Med2023; 29: 2187–2199.
42.
HansenDVHansonJEShengM. Microglia in Alzheimer's disease. J Cell Biol2018; 217: 459–472.
43.
ScheltensPDe StrooperBKivipeltoM, et al.Alzheimer's disease. Lancet2021; 397: 1577–1590.
44.
Esquerda-CanalsGMontoliu-GayaLGuell-BoschJ, et al.Mouse models of Alzheimer's disease. J Alzheimers Dis2017; 57: 1171–1183.
45.
ChenZYZhangY. Animal models of Alzheimer's disease: applications, evaluation, and perspectives. Zool Res2022; 43: 1026–1040.
46.
ZakariaRWan YaacobWMOthmanZ, et al.Lipopolysaccharide-induced memory impairment in rats: a model of Alzheimer's disease. Physiol Res2017; 66: 553–565.
47.
PuzzoDGulisanoWPalmeriA, et al.Rodent models for Alzheimer's disease drug discovery. Expert Opin Drug Discov2015; 10: 703–711.
48.
PodlisnyMBTolanDRSelkoeDJ. Homology of the amyloid beta protein precursor in monkey and human supports a primate model for beta amyloidosis in Alzheimer's disease. Am J Pathol1991; 138: 1423–1435.
49.
XuCZhaoLDongC. A review of application of Abeta42/40 ratio in diagnosis and prognosis of Alzheimer's disease. J Alzheimers Dis2022; 90: 495–512.
50.
BehzadMZirakNMadaniGH, et al.CSF-targeted proteomics indicate amyloid-beta ratios in patients with Alzheimer's dementia spectrum. Int J Alzheimers Dis2023; 2023: 5336273.
51.
ScheltensPBlennowKBretelerMM, et al.Alzheimer's disease. Lancet2016; 388: 505–517.
52.
PournelleMBRumbaughDM. A modified Wisconsin general test apparatus for use with a variety of small primates. Percept Mot Skills1965; 21: 489–490.
53.
BrandoSBasomLBashawM, et al.Individualized target training facilitated transfer of group housed capuchin monkeys (sapajus apella) to test cubicles and discrimination of targets on computer touch screens. Animals (Basel)2021; 11: 2070.
54.
OhMOhSJLeeSJ, et al.One-year longitudinal changes in tau accumulation on [(18)F]PI-2620 PET in the Alzheimer spectrum. J Nucl Med2024; 65: 453–461.
55.
BlazhenetsGSoleimani-MeigooniDNThomasW, et al.[(18)F]PI-2620 binding patterns in patients with suspected Alzheimer disease and frontotemporal lobar degeneration. J Nucl Med2023; 64: 1980–1989.
56.
XuXRuanWLiuF, et al.(18)F-APN-1607 tau positron emission tomography imaging for evaluating disease progression in Alzheimer's disease. Front Aging Neurosci2021; 13: 789054.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
